Nutex Health Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and net income grew year-over-year, while adjusted EBITDA declined due to arbitration cost timing. Cash flow and liquidity remain strong, with new hospital openings and direct development initiatives supporting future growth. Legislative and payer dynamics continue to influence reimbursement.
-
The meeting covered director elections, executive compensation, and auditor ratification, with all proposals approved by the required majority. Voting results will be reported on Form 8-K within four business days.
Fiscal Year 2025
-
Revenue grew 82% to $875.3M in 2025, with net income up to $70.8M and adjusted EBITDA rising 152.6%. Despite a one-time $55M Q4 revenue reduction from arbitration true-up, cash flow and patient volumes remained strong, supporting continued expansion and high patient satisfaction.
-
Q2 and Q3 2025 saw record revenue and profitability, driven by hospital division growth, improved margins, and strong cash flow. Expansion continues with new hospitals and IPA growth, while reliance on the IDR process and payer negotiations remain key factors.
-
The company is expanding its micro-hospital network, focusing on concierge-level care and strong physician alignment. After a regulatory-driven revenue drop in 2022, it restored profitability by increasing patient volume and leveraging arbitration for fair reimbursement. Growth is driven by new construction, acquisitions, and integrated population health strategies.
-
Q2 2025 delivered 220% revenue growth and a 51% gross margin, driven by strong patient volume and arbitration wins under the No Surprises Act. The company is addressing a non-cash restatement and maintains a robust development pipeline, with high patient satisfaction and a $25M stock buyback authorized.
-
Q1 2025 delivered record revenue and profitability, driven by arbitration collections and strong patient growth. Cash flow and margins improved significantly, with three new Texas hospitals set to open in late 2025 and a robust project pipeline supporting future expansion.
Fiscal Year 2024
-
Revenue nearly doubled in 2024, driven by arbitration wins and higher patient volume, with net income swinging positive and gross margins sharply improving. Expansion continued with four new hospitals, and cost controls offset inflation. Arbitration remains a key revenue driver.
-
Q3 2024 saw 26% revenue growth and a sharp rise in Adjusted EBITDA, driven by new and mature hospitals. Net loss widened due to non-cash items, but operational cash flow and margins improved. Two new hospitals are set to open in Q4, with four more planned for 2025.
-
Q2 2024 saw 29% revenue growth, a return to profitability, and strong hospital visit increases. Divestitures and operational efficiencies improved margins, while new hospital openings and arbitration efforts are expected to drive further gains.